Key Points
- Chairman Jurgi Camblong sold 40,172 shares of SOPHiA GENETICS at an average price of $8.13, generating approximately $326,600. He retained about 3.4 million shares after the transaction.
- The sale was conducted under a pre-arranged Rule 10b5-1 plan to cover tax-withholding obligations tied to vested equity awards, rather than representing a discretionary sale.
- SOPHiA GENETICS shares opened at $7.15, while analysts maintain a consensus “Hold” rating and $10 price target. The company recently missed quarterly EPS estimates despite reporting revenue above expectations.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CFO George Cardoza sold 1,592 shares of SOPHiA GENETICS stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $8.10, for a total transaction of $12,895.20. Following the completion of the transaction, the chief financial officer directly owned 306,726 shares of the company's stock, valued at $2,484,480.60. This trade represents a 0.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
George Cardoza also recently made the following trade(s):
- On Monday, September 21st, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.33, for a total transaction of $6,447.42.
SOPHiA GENETICS Price Performance
Shares of SOPH opened at $7.15 on Thursday. The company has a market capitalization of $599.81 million, a P/E ratio of -6.22 and a beta of 0.95. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The firm has a 50 day moving average of $7.85 and a 200 day moving average of $6.14. SOPHiA GENETICS SA has a twelve month low of $3.75 and a twelve month high of $8.98.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to analysts' expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.
Key Stories Impacting SOPHiA GENETICS
Here are the key news stories impacting SOPHiA GENETICS this week:
- Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00, implying potential upside from recent trading levels. The target supports the view that analysts see additional value in SOPHiA GENETICS’ genomic-data and diagnostics platform. SOPHiA GENETICS consensus target price article
- Neutral Sentiment: A separate report compared SOPHiA GENETICS with Weave Communications. The comparison provides relative context for investors but does not appear to announce a material operational or financial development for SOPH. Weave Communications versus SOPHiA GENETICS comparison
- Negative Sentiment: Multiple executives and directors sold shares on October 5 at approximately $8.04–$8.13, totaling about $669,000. Sellers included CEO Ross Muken, Chairman Jurgi Camblong, CFO George Cardoza, CTO Abhimanyu Verma and other insiders. The broad number of sellers can weigh on sentiment and may be contributing to recent weakness.
- Negative Sentiment: The filings state that all reported transactions were conducted under pre-arranged Rule 10b5-1 plans and were intended to cover tax-withholding obligations tied to vested equity awards. This reduces the significance of the sales as a discretionary bearish signal, although the transactions still add near-term selling pressure. Most insiders retained substantial holdings after the sales, including the chairman’s approximately 3.4 million shares and the CEO’s roughly 660,000 shares.
Institutional Investors Weigh In On SOPHiA GENETICS
Several institutional investors and hedge funds have recently added to or reduced their stakes in SOPH. AWM Investment Company Inc. bought a new stake in SOPHiA GENETICS in the 2nd quarter worth approximately $9,809,000. Principal Financial Group Inc. lifted its holdings in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after buying an additional 9,800 shares during the period. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 1st quarter valued at $2,157,000. Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS in the 1st quarter worth $1,772,000. Finally, 1492 Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company's stock worth $1,117,000 after buying an additional 17,406 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company's stock.
Wall Street Analyst Weigh In
SOPH has been the subject of several recent analyst reports. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. BTIG Research increased their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, SOPHiA GENETICS presently has a consensus rating of "Hold" and an average target price of $10.00.
View Our Latest Report on SOPHiA GENETICS
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.
The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
